---
abstract: Pre-existing and acquired drug resistance are major obstacles to the successful
  treatment of glioblastomas.
authors: Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, Vogel H, Recht LD,
  Scheck AC and Sikic BI.
cancertypes:
- term_id: ncit:C3058
  term_label: Glioblastoma
- term_id: pgx:icdom:9440_3
  term_label: Glioblastoma, NOS
- term_id: pgx:icdot:C71.9
  term_label: Brain, NOS
- term_id: pgx:seer:31010
  term_label: Brain
- term_id: snmi:M-94403
  term_label: Glioblastoma, NOS
contact:
  email: mbredel@stanford.edu
  name: Markus Bredel
counts:
  biosamples: 30
  samples_acgh: 30
  samples_ccgh: 0
  samples_wes: 0
  samples_wgs: 0
external_identifiers:
- pubmed:16365179
- geo:GSE2221
geo_data:
  geo_json:
    coordinates:
    - -122.17
    - 37.43
    type: Point
  info:
    city: Stanford
    continent: North America
    country: United States
    label: Stanford, United States, North America
    precision: city
journal: 'J Clin Oncol 24, 2 (2006): 274-87.'
label: 'Bredel et al. (2006): Tumor Necrosis Factor-Alpha-Induced Protein 3 as a Putative
  Regulator of Nuclear ...'
notes: ~
pmid: 16365179
title: Tumor Necrosis Factor-Alpha-Induced Protein 3 as a Putative Regulator of Nuclear
  Factor-Kappab-Mediated Resistance to O6-Alkylating Agents in Human Glioblastomas.
year: 2006
